Pasithea Therapeutics (KTTA) reported Friday it priced a public offering of 80 million shares or pre-funded warrants at $0.75 each, targeting $60 million in gross proceeds.

The net proceeds will be used for general corporate purposes, including research, clinical trials, and potential acquisitions or licensing activities.

Shares surged 54% as intraday trading volume catapulted to over 155.3 million from a daily average of about 3.9 million.

HeartBeam (BEAT) said late Wednesday it received a "Not Substantially Equivalent" decision from the US Food and Drug Administration on its 12-lead ECG synthesis software submission, and said it is actively engaging with the agency on multiple regulatory paths, including potential labeling modifications.

The company said its supporting clinical study met its endpoints and believes remaining FDA concerns can be addressed.

Shares jumped 24%, with intraday trading volume at over 96.9 million compared with a daily average of about 425,000.

Price: 1.63, Change: +0.57, Percent Change: +53.77